American Vanguard (AVD) 10-Q 4 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 25, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	AVD
Entity Registrant Name	AMERICAN VANGUARD CORP
Entity Central Index Key	5,981
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		29,149,049

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net sales	$ 69,474	$ 66,565
Cost of sales	41,971	41,915
Gross profit	27,503	24,650
Operating expenses	22,873	24,344
Operating income	4,630	306
Interest expense	541	641
Income (loss) before provision for income taxes and loss on equity investment	4,089	(335)
Income taxes expense (benefit)	1,060	(292)
Income (loss) before loss on equity investment	3,029	(43)
Net loss from equity method investment	(82)
Net income (loss)	2,947	(43)
Net (income) loss attributable to non-controlling interest	(153)	94
Net income attributable to American Vanguard	$ 2,794	$ 51
Earnings per common share-basic	$ 0.10	$ 0
Earnings per common share-assuming dilution	$ 0.10	$ 0
Weighted average shares outstanding-basic	28,808	28,527
Weighted average shares outstanding-assuming dilution	29,307	28,839

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 7,916	$ 5,524
Receivables:
Trade, net of allowance for doubtful accounts of $388 and $423, respectively	82,687	72,835
Other	2,904	2,554
Total receivables, net	85,591	75,389
Inventories	144,415	136,477
Prepaid expenses	12,354	11,172
Income taxes receivable		168
Deferred income tax assets	8,101	8,101
Total current assets	258,377	236,831
Property, plant and equipment, net	46,433	47,972
Intangible assets, net of applicable amortization	127,131	129,160
Other assets	31,581	29,576
Total assets	463,522	443,539
Current liabilities:
Current installments of other notes payable	37	55
Current installments of other liabilities	200	514
Accounts payable	28,374	15,343
Deferred revenue	7,040	8,888
Accrued program costs	52,002	44,371
Accrued expenses and other payables	6,992	7,111
Income tax payable	1,002
Total current liabilities	95,647	76,282
Long-term debt and other notes payable, excluding current installments	65,763	68,321
Other liabilities, excluding current installments	3,022	3,054
Deferred income tax liabilities	27,556	27,556
Total liabilities	$ 191,988	$ 175,213
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 31,596,302 shares at March 31, 2016 and 31,638,225 shares at December 31, 2015	$ 3,160	$ 3,164
Additional paid-in capital	68,714	68,534
Accumulated other comprehensive loss	(3,456)	(3,541)
Retained earnings	211,301	208,507
Total stockholders' equity including treasury stock	279,719	276,664
Less treasury stock at cost, 2,450,634 shares at March 31, 2016 and December 31, 2015	(8,269)	(8,269)
American Vanguard Corporation stockholders' equity	271,450	268,395
Non-controlling interest	84	(69)
Total stockholders' equity	271,534	268,326
Total liabilities and stockholders' equity	$ 463,522	$ 443,539

CONDENSED CONSOLIDATED BALANCE4

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Allowance for doubtful accounts	$ 388	$ 423
Preferred stock, par value per share	$ 0.10	$ 0.10
Preferred stock, shares authorized	400,000	400,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.10	$ 0.10
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	31,596,302	31,638,225
Treasury stock, shares	2,450,634	2,450,634

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - 3 months ended Mar. 31, 2016 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income/(loss)	Retained Earnings	Treasury Stock	AVD Total	Non- Controlling Interest
Balance (in shares) at Dec. 31, 2015	31,638,225	31,638,225				2,450,634
Balance at Dec. 31, 2015	$ 268,326	$ 3,164	$ 68,534	$ (3,541)	$ 208,507	$ (8,269)	$ 268,395	$ (69)
Stocks issued under ESPP (in shares)		19,627
Stocks issued under ESPP	271	$ 2	269				271
Foreign currency translation adjustment, net	85			85			85
Stock based compensation	456		456				456
Stock options exercised and grants and vesting of restricted stock units	(586)	$ (6)	(580)				(586)
Stock options exercised and grants and vesting of restricted stock units, Shares		(61,550)
Excess tax benefits from share based payment arrangements	35		35				35
Net income	$ 2,947				2,794		2,794	153
Balance (in shares) at Mar. 31, 2016	31,596,302	31,596,302				2,450,634
Balance at Mar. 31, 2016	$ 271,534	$ 3,160	$ 68,714	$ (3,456)	$ 211,301	$ (8,269)	$ 271,450	$ 84

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net income attributable to American Vanguard	$ 2,794	$ 51
Foreign currency translation adjustment	85	(248)
Comprehensive income (loss)	$ 2,879	$ (197)

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net income (loss)	$ 2,947	$ (43)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization of fixed and intangible assets	4,315	3,954
Amortization of other long term assets	1,092	1,430
Amortization of discounted liabilities	9	49
Stock-based compensation	456	1,427
Tax benefit from exercise of stock options	(35)	(1)
Operating loss from equity method investment	82
Changes in assets and liabilities associated with operations:
(Increase) decrease in net receivables	(10,202)	3,611
Increase in inventories	(7,938)	(1,350)
Increase in prepaid expenses and other assets	(1,036)	(1,301)
Decrease (increase) in income tax receivable/payable, net	1,205	(378)
Increase in accounts payable	13,031	3,570
(Decrease) increase in deferred revenue	(1,848)	3,660
Increase in other payables and accrued expenses	7,512	5,214
Net cash provided by operating activities	9,590	19,842
Cash flows from investing activities:
Capital expenditures	(715)	(1,522)
Investment	(3,283)
Net cash used in investing activities	(3,998)	(1,522)
Cash flows from financing activities:
Net payments under line of credit agreement	(2,600)	(14,400)
Payments on other long-term liabilities	(373)	(351)
Tax benefit from exercise of stock options	35	1
Increase in other notes payable		200
Net payments from the issuance of common stock (sale of stock under ESPP and exercise of stock options)	(315)	(965)
Payment of cash dividends		(569)
Net cash used in by financing activities	(3,253)	(16,084)
Net increase in cash and cash equivalents	2,339	2,236
Cash and cash equivalents at beginning of period	5,524	4,885
Effect of exchange rate changes on cash	53	(251)
Cash and cash equivalents at end of period	$ 7,916	$ 6,870

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Summary of Significant Accounting Policies	1. The accompanying unaudited condensed consolidated financial statements of American Vanguard Corporation and Subsidiaries (“AVD”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation, have been included. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment	2. Property, plant and equipment at March 31, 2016 and December 31, 2015 consists of the following: March 31, December 31, Land $ 2,458 $ 2,458 Buildings and improvements 14,982 14,726 Machinery and equipment 116,818 113,506 Office furniture, fixtures and equipment 4,895 4,997 Automotive equipment 510 491 Construction in progress 516 3,413 140,179 139,591 Less accumulated depreciation (93,746 ) (91,619 ) $ 46,433 $ 47,972 The Company recognized depreciation expense related to property and equipment of $2,254 and $2,361 for the three months ended March 31, 2016 and 2015, respectively. During the three months ended March 31, 2016 and 2015, the Company eliminated from assets and accumulated depreciation $127 and $136, respectively, of fully depreciated assets. Substantially all of the Company’s assets are pledged as collateral with its banks.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2016
Inventories	3. Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out method. The components of inventories consist of the following: March 31, December 31, Finished products $ 124,425 $ 120,456 Raw materials 19,990 16,021 $ 144,415 $ 136,477

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2016
Segment Reporting	4. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information is as follows: Three Months Ended 2016 2015 Net sales: Insecticides $ 33,106 $ 34,359 Herbicides/soil fumigants/fungicides 24,685 21,840 Other, including plant growth regulators 3,277 3,322 61,068 59,521 Non-crop 8,406 7,044 $ 69,474 $ 66,565 Net sales: US $ 49,985 $ 49,222 International 19,489 17,343 $ 69,474 $ 66,565

Accrued Program Costs

Accrued Program Costs	3 Months Ended
	Mar. 31, 2016
Accrued Program Costs	5. Accrued Program Costs

Cash Dividend

Cash Dividend	3 Months Ended
	Mar. 31, 2016
Cash Dividend	6. The Company has declared and paid prior periods the following cash dividends in the periods covered by this Form 10-Q: Declaration Date Record Date Distribution Date Dividend Per Share Total Paid March 16, 2015 April 3, 2015 April 17, 2015 $ 0.02 $ 572 December 11, 2014 December 26, 2014 January 9, 2015 $ 0.02 $ 569

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share	7. ASC 260 Earnings Per Share (“EPS” The components of basic and diluted earnings per share were as follows: Three Months Ended 2016 2015 Numerator: Net income attributable to AVD $ 2,794 $ 51 Denominator: Weighted averages shares outstanding-basic 28,808 28,527 Dilutive effect of stock options and grants 499 312 29,307 28,839 For the three months ended March 31, 2016, no stock options were excluded from the computation of diluted earnings per share. The Company excluded 276,654 stock options from the computation of diluted earnings per share for the three months ended March 31, 2015 because to include those options would be anti-dilutive.

Indebtedness

Indebtedness	3 Months Ended
	Mar. 31, 2016
Indebtedness	8. The Company has a revolving line of credit and various notes payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at March 31, 2016 and December 31, 2015. These are summarized in the following table: Indebtedness March 31, 2016 December 31, 2015 $000’s Long- Short- Total Long- Short- Total Revolving line of credit $ 66,400 $ — $ 66,400 $ 69,000 $ — $ 69,000 Deferred loan fees (637 ) — (637 ) (679 ) — (679 ) Notes payable — 37 37 — 55 55 Total indebtedness $ 65,763 $ 37 $ 65,800 $ 68,321 $ 55 $ 68,376 AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, are parties to a credit agreement dated as of July 11, 2014 (the “Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and L/C issuer. The Credit Agreement is a senior secured lending facility with a five year term and consisting of a revolving line of credit of $200 million and an accordion feature for up to $100 million. The Credit Agreement includes both AMVAC CV and AMVAC BV as borrowers. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”). Interest payments for Eurocurrency Rate Loans are payable on the last day of each interest period (either one, two, three or six months, as selected by the borrower) and the maturity date, while interest payments for Alternate Base Rate Loans are payable on the last business day of each month and the maturity date. The senior secured revolving line of credit matures on June 17, 2018. Under the Credit Agreement, the Company has three key covenants (with which it was in compliance throughout the three months ended March 31, 2016). The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio, (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio. As of April 14, 2015, AMVAC, registrant’s principal operating subsidiary, as borrower, and affiliates (including registrant), as guarantors and/or borrowers, entered into an amendment to the Credit Agreement under which, the Consolidated Funded Debt Ratio was increased for the second, third and fourth quarters of 2015 (to 3.5-to-1 from 3.25-to-1) and a fixed charge covenant, requiring, in effect, that the ratio of consolidated current assets to consolidated current liabilities exceed 1.2-to-1 for the duration of the term of the credit facility, was added. At March 31, 2016, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $65,373, according to the terms of the Credit Agreement. This compares to an available borrowing capacity of $22,710 as of March 31, 2015. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for trailing twelve month period, has improved, (2) borrowings have decreased notwithstanding the product line acquisitions completed in the second quarter of 2015 and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement) is lower when compared with the earlier period.

Reclassification

Reclassification	3 Months Ended
	Mar. 31, 2016
Reclassification	9. Reclassification—Certain items may have been reclassified in the prior period condensed consolidated financial statements to conform with the March 31, 2016 presentation.

Comprehensive income (loss)

Comprehensive income (loss)	3 Months Ended
	Mar. 31, 2016
Comprehensive income (loss)	10. Total comprehensive income (loss) includes, in addition to net income, changes in equity that are excluded from the condensed consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the condensed consolidated balance sheets. For the three month period ended March 31, 2016, total comprehensive income consisted of net income attributable to American Vanguard and foreign currency translation adjustments.

Stock Based Compensation

Stock Based Compensation	3 Months Ended
	Mar. 31, 2016
Stock Based Compensation	11. Stock Based Compensation—The Company accounts for stock-based awards to employees and directors in accordance with FASB ASC 718, “ Share-Based Payment The below tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three months ended March 31, 2016 and 2015. Stock-Based Unamortized Remaining March 31, 2016 Incentive Stock Options $ 89 $ 746 1.7 Restricted Stock 326 1,462 1.4 Performance Based Restricted Stock 33 441 1.3 Performance Based Options 8 263 1.7 Total $ 456 $ 2,912 March 31, 2015 Incentive Stock Options $ 115 $ 1,336 2.7 Restricted Stock 1,172 4,010 1.3 Performance Based Restricted Stock 98 917 1.9 Performance Based Options 42 499 2.8 Total $ 1,427 $ 6,762 Stock Options—During the three months ended March 31, 2016, the Company did not grant any employees options to acquire shares of common stock. Option activity within each plan is as follows: Incentive Weighted Average Exercisable Balance outstanding, December 31, 2015 626,845 $ 9.25 $ 7.73 Options exercised (25,500 ) 7.50 Options forfeited (9,813 ) 11.49 Balance outstanding, March 31, 2016 591,532 $ 9.29 $ 7.84 Information relating to stock options at March 31, 2016 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Exercise Price Per Share Shares Remaining Exercise Shares Exercise Incentive Stock Option Plan: $7.50 331,750 56 $ 7.5 331,750 $ 7.50 $11.32—$14.49 259,782 101 $ 11.57 25,507 $ 12.28 591,532 $ 9.29 357,257 $ 7.84 The weighted average exercise prices for options granted, and exercisable and the weighted average remaining contractual life for options outstanding as of March 31, 2016 were as follows: Number Weighted Weighted Intrinsic As of March 31, 2016: Incentive Stock Option Plans: Outstanding 591,532 $ 9.29 76 $ 3,841 Expected to Vest 582,606 $ 9.25 76 $ 3,803 Exercisable 357,257 $ 7.84 57 $ 2,836 During the three months ended March 31, 2016 and 2015, the Company recognized stock-based compensation related to stock options of $89 and $115, respectively. As of March 31, 2016 and 2015, the Company had approximately $746 and $1,336, respectively, of unamortized stock-based compensation related to unvested stock options outstanding. This amount will be recognized over the weighted-average period of 1.7 and 2.7 years. This projected expense will change if any stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Restricted Shares — Three Months Ended Three Months Ended Number Weighted Number Weighted Nonvested shares at January 1 st 362,841 $ 20.43 560,842 $ 21.44 Granted — — 30,000 11.42 Vested (127,274 ) 31.29 (192,266 ) 20.47 Forfeited (16,008 ) 23.67 (422 ) 14.92 Nonvested shares at March 31 st 219,559 $ 14.59 398,154 $ 21.17 Restricted Shares — During the three months ended March 31, 2016, the Company issued a total of 119,402 shares of restricted common stock to employees. The issued shares are subject to stockholder approval at which point the shares will be fair valued. The shares will cliff vest after three years of service. The fair value will be determined by using the publicly traded share price as of the date of grant. The Company will recognize as expense the value of restricted shares over the required service period from grant date. These shares have been excluded from the table above. During the three months ended March 31, 2015, the Company granted a total of 30,000 shares of common stock. Of these, 7,500 shares vested after 90 days from the date of grant and the balance will cliff vest after three years of services. The shares granted in 2015 were average fair valued at $11.42 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company is recognizing as expense the value of restricted shares over the required service period. During the three months ended March 31, 2016 and 2015, the Company recognized stock-based compensation related to restricted shares of $326 and $1,172, respectively. As of March 31, 2016 and 2015, the Company had approximately $1,462 and $4,010, respectively, of unamortized stock-based compensation related to unvested restricted shares. This amount will be recognized over the weighted-average period of 1.4 and 1.3 years. This projected expense will change if any restricted shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Based Shares—A summary of non-vested performance based shares as of and for the three months ended March 31, 2016 and 2015 is presented below: Three Months Ended Three Months Ended Number Weighted Number Weighted Nonvested shares at January 1 st 104,403 $ 17.05 103,907 $ 17.77 Granted — — 7,500 10.96 Forfeited (9,395 ) 17.65 — — Nonvested shares at March 31 st 95,008 $ 16.99 111,407 $ 17.31 Performance Based Shares — During the three months ended March 31, 2016, the Company issued a total of 52,170 performance based shares to employees. The issued shares are subject to stockholder approval at which point the shares will be fair valued. The fair value will be determined by using the publicly traded share price as of the date of grant. The Company will recognize as expense the value of the performance based shares over the required service period from grant date. The shares will cliff vest on January 6, 2019 with a measurement period commencing January 1, 2016 and ending December 31, 2018. Eighty percent of these performance based shares are based upon the financial performance of the Company, specifically, an earnings before income tax (“EBIT”) goal weighted at 50% and a net sales goal weighted at 30%. The remaining 20% of performance based shares are based upon AVD stock price appreciation over the same performance measurement period. The EBIT and net sales goals measure the relative growth of the Company’s EBIT and net sales for the performance measurement period, as compared to the median growth of EBIT and net sales for an identified peer group. The stockholder return goal measures the relative growth of the fair market value of the Company’s stock price over the performance measurement period, as compared to that of the Russell 2000 Index and the median fair market value of the common stock of the comparator companies, identified in the Company’s 2015 Proxy Statement. All parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for meeting less than the targeted performance and to increase to a maximum of 200% for meeting in excess of the targeted performance. These shares have been excluded from the table above. During the three months ended March 31, 2015, the Company granted a total of 7,500 performance based shares that will cliff vest on January 5, 2018. Eighty percent of these performance based shares are based upon the financial performance of the Company, specifically, an earnings before income tax (“EBIT”) goal weighted at 50% and a net sales goal weighted at 30%. The remaining 20% of performance based shares are based upon AVD stock price appreciation over the same performance measurement period. The EBIT and net sales goals measure the relative growth of the Company’s EBIT and net sales for the performance measurement period, as compared to the median growth of EBIT and net sales for an identified peer group. The stockholder return goal measures the relative growth of the fair market value of the Company’s stock price over the performance measurement period, as compared to that of the Russell 2000 Index and the median fair market value of the common stock of the comparator companies, identified in the Company’s 2014 Proxy Statement. All parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for meeting less than the targeted performance and to increase to a maximum of 200% for meeting in excess of the targeted performance. As of March 31, 2015, performance based shares related to net income and net sales have an average fair value of $11.42 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The performance based shares related to the Company’s stock price have an average fair value of $9.13 per share. The fair value was determined by using the Monte Carlo valuation method. For awards with performance conditions, the Company recognizes share-based compensation cost on a straight-line basis for each performance criteria over the implied service period. During the three months ended March 31, 2016 and 2015, the Company recognized stock-based compensation related to performance based shares of $33 and $98, respectively. As of March 31, 2016 and 2015, the Company had approximately $441 and $917, respectively, of unamortized stock-based compensation expense related to unvested performance based shares. This amount will be recognized over the weighted-average period of 1.3 and 1.9 years. This projected expense will change if any performance based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures. Performance Incentive Stock Options—During the three months ended March 31, 2016 and 2015, the Company did not grant any employees performance incentive stock options to acquire shares of common stock. Performance option activity is as follows: Incentive Weighted Average Exercisable Balance outstanding, December 31, 2015 98,410 $ 11.49 $ — Options forfeited (8,946 ) 11.49 — Balance outstanding, March 31, 2016 89,464 $ 11.49 $ — Information relating to stock options at March 31, 2016 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Exercise Price Per Share Shares Remaining Exercise Shares Exercise Performance Incentive Stock Option Plan: $11.49 89,464 21 $ 11.49 — $ — 89,464 $ 11.49 — $ — The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of March 31, 2016 are as follows: Number Weighted Weighted Intrinsic As of March 31, 2016: Incentive Stock Option Plans: Outstanding 89,464 $ 11.49 21 $ 384 Expected to Vest 53,603 $ 11.49 21 $ 230 Exercisable — $ — — $ — During the three months ended March 31, 2016 and 2015 the Company recognized stock-based compensation related to performance stock options of $8 and $42, respectively. As of March 31, 2016 and 2015, the Company had approximately $263 and $499, respectively, of unamortized stock-based compensation expenses related to unvested performance incentive stock options outstanding. This amount will be recognized over the weighted-average period of 1.7 and 2.8 years. This projected expense will change if any performance incentive stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

Legal Proceedings

Legal Proceedings	3 Months Ended
	Mar. 31, 2016
Legal Proceedings	12. Legal Proceedings— During the reporting period, there have been no material developments in legal proceedings that were reported in the Company’s Form 10-K for the period ended December 31, 2015, except as described below. Galvan v. AMVAC Graciela Galvan v. AMVAC Chemical Corp. Navarro v. AMVAC Schiemer Farms v. AMVAC U.S. EPA RCRA/FIFRA Matter

Recently Issued Accounting Guid

Recently Issued Accounting Guidance	3 Months Ended
	Mar. 31, 2016
Recently Issued Accounting Guidance	13. Recently Issued Accounting Guidance—In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation (Topic 718) In March 2016, FASB issued ASU 2016-07, Investments – Equity Method and Joint Ventures In February 2016, FASB issued ASU 2016-02, Leases In January 2016, FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes. In July 2015, FASB issued ASU 2015-11, Inventory (Topic 330) In August 2014, FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. In June 2014, FASB issued ASU 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, a consensus of the FASB Emerging Issues Task Force In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2016
Fair Value of Financial Instruments	14. Fair Value of Financial Instruments—The carrying values of cash, receivables and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the Company’s long-term debt and note payable to the bank is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. Such fair value approximates the respective carrying values of the Company’s long-term debt and note payable to bank.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income ("AOCI")	3 Months Ended
	Mar. 31, 2016
Accumulated Other Comprehensive Income ("AOCI")	15. Accumulated Other Comprehensive Income (“AOCI”)—The following table lists the beginning balance, annual activity and ending balance of accumulated other comprehensive loss, which consists of foreign currency translation adjustments: For the Three Months Ended March 31, 2016 Balance, December 31, 2015 $ (3,541 ) Other comprehensive gain 85 Balance, March 31, 2016 $ (3,456 ) For the Three Months Ended March 31, 2015 Balance, December 31, 2014 $ (1,970 ) Other comprehensive loss (248 ) Balance, March 31, 2015 $ (2,218 )

Equity Investment

Equity Investment	3 Months Ended
	Mar. 31, 2016
Equity Investment	16. The Company utilizes the equity method of accounting with respect to its investment in TyraTech Inc. (“TyraTech”), a Delaware corporation that specializes in developing, marketing and selling pesticide products containing natural oils. As of March 31, 2016, the Company’s ownership position in TyraTech was approximately 15.11%. The Company utilizes the equity method of accounting with respect to this investment. As a result, our net income includes losses from equity method investments, which represents our proportionate share of TyraTech’s estimated net losses for the current accounting period. For the three months ended March 31, 2016, the Company recognized a loss of $82 as a result of the Company’s ownership position in TyraTech. The Company’s investment in TyraTech is included in other assets on the condensed consolidated balance sheets. At March 31, 2016, the carrying value of the Company’s investment in TyraTech was $2,454 and the quoted market value of its shareholding was $2,395 based on the London Stock Exchange, Alternative Investment Market (“AIM”). At March 31, 2016, the Company performed an impairment review of its investment in TyraTech and concluded that no impairment charge was appropriate.
Biological Products For Agriculture
Equity Investment	17. In February 2016, the Company made an equity investment in Biological Products for Agriculture (“Bi-PA”) through its Netherlands wholly-owned subsidiary. Bi-PA develops biological plant protection products that can be used for the control of pests and disease of agricultural crops. As of March 31, 2016, the Company’s ownership position in Bi-PA was 15%. The Company utilizes the cost method of accounting with respect to this investment and will periodically review the investment for possible impairment. There was no impairment on the investment as of March 31, 2016. The investment is recorded within other assets on the condensed consolidated balance sheets.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Taxes	18. Income Taxes – Income tax expense was $1,060 for the three months ended March 31, 2016, as compared to an income tax benefit of $292 for the three months ended March 31, 2015. The effective tax rate was 25.9% (which was a tax expense) in 2016 and 87.2% (which was a tax benefit) in 2015. The effective tax rate for the three months ended March 31, 2016 is based on the projected income for the full year and is subject to ongoing review and adjustment by management. The Company has been notified by the IRS of its intent to examine the Company’s federal income tax returns for the years ended December 31, 2012 through December 31, 2014. Currently the results of the audit are not determinable since the audit is still in its initial phase.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2016
Summary of Property, Plant and Equipment	Property, plant and equipment at March 31, 2016 and December 31, 2015 consists of the following: March 31, December 31, Land $ 2,458 $ 2,458 Buildings and improvements 14,982 14,726 Machinery and equipment 116,818 113,506 Office furniture, fixtures and equipment 4,895 4,997 Automotive equipment 510 491 Construction in progress 516 3,413 140,179 139,591 Less accumulated depreciation (93,746 ) (91,619 ) $ 46,433 $ 47,972

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2016
Components of Inventories	The components of inventories consist of the following: March 31, December 31, Finished products $ 124,425 $ 120,456 Raw materials 19,990 16,021 $ 144,415 $ 136,477

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2016
Summary of Business Sales Segmentation	Selective enterprise information is as follows: Three Months Ended 2016 2015 Net sales: Insecticides $ 33,106 $ 34,359 Herbicides/soil fumigants/fungicides 24,685 21,840 Other, including plant growth regulators 3,277 3,322 61,068 59,521 Non-crop 8,406 7,044 $ 69,474 $ 66,565 Net sales: US $ 49,985 $ 49,222 International 19,489 17,343 $ 69,474 $ 66,565

Cash Dividend (Tables)

Cash Dividend (Tables)	3 Months Ended
	Mar. 31, 2016
Cash Dividend	The Company has declared and paid prior periods the following cash dividends in the periods covered by this Form 10-Q: Declaration Date Record Date Distribution Date Dividend Per Share Total Paid March 16, 2015 April 3, 2015 April 17, 2015 $ 0.02 $ 572 December 11, 2014 December 26, 2014 January 9, 2015 $ 0.02 $ 569

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2016
Components of Basic and Diluted Earnings Per Share	The components of basic and diluted earnings per share were as follows: Three Months Ended 2016 2015 Numerator: Net income attributable to AVD $ 2,794 $ 51 Denominator: Weighted averages shares outstanding-basic 28,808 28,527 Dilutive effect of stock options and grants 499 312 29,307 28,839

Indebtedness (Tables)

Indebtedness (Tables)	3 Months Ended
	Mar. 31, 2016
Summary of Short-Term and Long-Term Loan Balances in Condensed Consolidated Balance Sheets	The Company has a revolving line of credit and various notes payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at March 31, 2016 and December 31, 2015. These are summarized in the following table: Indebtedness March 31, 2016 December 31, 2015 $000’s Long- Short- Total Long- Short- Total Revolving line of credit $ 66,400 $ — $ 66,400 $ 69,000 $ — $ 69,000 Deferred loan fees (637 ) — (637 ) (679 ) — (679 ) Notes payable — 37 37 — 55 55 Total indebtedness $ 65,763 $ 37 $ 65,800 $ 68,321 $ 55 $ 68,376

Stock Based Compensation (Table

Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Stock Based Compensation, Unamortized Stock-Based Compensation and Remaining Weighted Average Period	The below tables illustrate the Company’s stock based compensation, unamortized stock-based compensation, and remaining weighted average period for the three months ended March 31, 2016 and 2015. Stock-Based Unamortized Remaining March 31, 2016 Incentive Stock Options $ 89 $ 746 1.7 Restricted Stock 326 1,462 1.4 Performance Based Restricted Stock 33 441 1.3 Performance Based Options 8 263 1.7 Total $ 456 $ 2,912 March 31, 2015 Incentive Stock Options $ 115 $ 1,336 2.7 Restricted Stock 1,172 4,010 1.3 Performance Based Restricted Stock 98 917 1.9 Performance Based Options 42 499 2.8 Total $ 1,427 $ 6,762
Summary of Option Activity	Option activity within each plan is as follows: Incentive Weighted Average Exercisable Balance outstanding, December 31, 2015 626,845 $ 9.25 $ 7.73 Options exercised (25,500 ) 7.50 Options forfeited (9,813 ) 11.49 Balance outstanding, March 31, 2016 591,532 $ 9.29 $ 7.84
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at March 31, 2016 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Exercise Price Per Share Shares Remaining Exercise Shares Exercise Incentive Stock Option Plan: $7.50 331,750 56 $ 7.5 331,750 $ 7.50 $11.32—$14.49 259,782 101 $ 11.57 25,507 $ 12.28 591,532 $ 9.29 357,257 $ 7.84
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted, and exercisable and the weighted average remaining contractual life for options outstanding as of March 31, 2016 were as follows: Number Weighted Weighted Intrinsic As of March 31, 2016: Incentive Stock Option Plans: Outstanding 591,532 $ 9.29 76 $ 3,841 Expected to Vest 582,606 $ 9.25 76 $ 3,803 Exercisable 357,257 $ 7.84 57 $ 2,836
Performance Based Options
Summary of Option Activity	Performance option activity is as follows: Incentive Weighted Average Exercisable Balance outstanding, December 31, 2015 98,410 $ 11.49 $ — Options forfeited (8,946 ) 11.49 — Balance outstanding, March 31, 2016 89,464 $ 11.49 $ —
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at March 31, 2016 summarized by exercise price is as follows: Outstanding Weighted Average Exercisable Weighted Exercise Price Per Share Shares Remaining Exercise Shares Exercise Performance Incentive Stock Option Plan: $11.49 89,464 21 $ 11.49 — $ — 89,464 $ 11.49 — $ —
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of March 31, 2016 are as follows: Number Weighted Weighted Intrinsic As of March 31, 2016: Incentive Stock Option Plans: Outstanding 89,464 $ 11.49 21 $ 384 Expected to Vest 53,603 $ 11.49 21 $ 230 Exercisable — $ — — $ —
Restricted Stock
Summary of Non-Vested Shares	Restricted Shares — Three Months Ended Three Months Ended Number Weighted Number Weighted Nonvested shares at January 1 st 362,841 $ 20.43 560,842 $ 21.44 Granted — — 30,000 11.42 Vested (127,274 ) 31.29 (192,266 ) 20.47 Forfeited (16,008 ) 23.67 (422 ) 14.92 Nonvested shares at March 31 st 219,559 $ 14.59 398,154 $ 21.17
Performance Shares
Summary of Non-Vested Shares	Performance Based Shares—A summary of non-vested performance based shares as of and for the three months ended March 31, 2016 and 2015 is presented below: Three Months Ended Three Months Ended Number Weighted Number Weighted Nonvested shares at January 1 st 104,403 $ 17.05 103,907 $ 17.77 Granted — — 7,500 10.96 Forfeited (9,395 ) 17.65 — — Nonvested shares at March 31 st 95,008 $ 16.99 111,407 $ 17.31

Accumulated Other Comprehensi32

Accumulated Other Comprehensive Income ("AOCI") (Tables)	3 Months Ended
	Mar. 31, 2016
Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Loss of Foreign Currency Translation Adjustments	The following table lists the beginning balance, annual activity and ending balance of accumulated other comprehensive loss, which consists of foreign currency translation adjustments: For the Three Months Ended March 31, 2016 Balance, December 31, 2015 $ (3,541 ) Other comprehensive gain 85 Balance, March 31, 2016 $ (3,456 ) For the Three Months Ended March 31, 2015 Balance, December 31, 2014 $ (1,970 ) Other comprehensive loss (248 ) Balance, March 31, 2015 $ (2,218 )

Summary of Property, Plant and

Summary of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	$ 140,179	$ 139,591
Less accumulated depreciation	(93,746)	(91,619)
Total Property, plant and equipment	46,433	47,972
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	2,458	2,458
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	14,982	14,726
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	116,818	113,506
Office furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	4,895	4,997
Automotive equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	510	491
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	$ 516	$ 3,413

Property, Plant And Equipment -

Property, Plant And Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Property, Plant and Equipment [Line Items]
Depreciation expense related to property and equipment	$ 2,254	$ 2,361
Elimination of Assets and Accumulated depreciation	$ 127	$ 136

Components of Inventories (Deta

Components of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Inventory [Line Items]
Finished products	$ 124,425	$ 120,456
Raw materials	19,990	16,021
Total Inventories	$ 144,415	$ 136,477

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016Segment
Number of reportable business segments	1

Summary of Business Sales Segme

Summary of Business Sales Segmentation as per Product (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net Sales:
Total crop	$ 61,068	$ 59,521
Non-crop	8,406	7,044
Net sales	69,474	66,565
Insecticides
Net Sales:
Total crop	33,106	34,359
Herbicides/Soil Fumigants/Fungicides
Net Sales:
Total crop	24,685	21,840
Other, Including Plant Growth Regulators
Net Sales:
Total crop	$ 3,277	$ 3,322

Summary of Business Sales Seg38

Summary of Business Sales Segmentation as per Location (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net Sales:
Net sales	$ 69,474	$ 66,565
US
Net Sales:
Net sales	49,985	49,222
International
Net Sales:
Net sales	$ 19,489	$ 17,343

Cash Dividend (Detail)

Cash Dividend (Detail) - USD ($) $ / shares in Units, $ in Thousands	Dec. 11, 2014	Mar. 31, 2016
Dividends [Line Items]
Cash dividend declaration date	Dec. 11, 2014	Mar. 16, 2015
Cash dividend distributed date	Dec. 26, 2014	Apr. 3, 2015
Cash dividend record date	Jan. 9, 2015	Apr. 17, 2015
Cash dividend per share	$ 0.02	$ 0.02
Cash dividend paid	$ 569	$ 572

Components of Basic and Diluted

Components of Basic and Diluted Earnings Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Numerator:
Net income attributable to AVD	$ 2,794	$ 51
Denominator:
Weighted average shares outstanding-basic	28,808	28,527
Dilutive effect of stock options and grants	499	312
Weighted average shares outstanding-assuming dilution	29,307	28,839

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Components Of Basic And Diluted Earning Per Share [Line Items]
Anti-dilutive stock options excluded from computation of diluted earning per share	0	276,654

Summary Revolving Line of Credi

Summary Revolving Line of Credit And Various Notes Payable Constitute Short-Term and Long-Term Loan Balances Together (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Extinguishment of Debt [Line Items]
Revolving line of credit, Long Term	$ 66,400	$ 69,000
Revolving line of credit, Short-term	0	0
Revolving line of credit	66,400	69,000
Deferred loan fees, Long Term	(637)	(679)
Deferred loan fees, Short-term	0	0
Deferred loan fees	(637)	(679)
Notes payable, Long Term	0	0
Notes payable, Short-term	37	55
Notes payable	37	55
Long Term debt	65,763	68,321
Short-term	37	55
Total indebtedness	$ 65,800	$ 68,376

Indebtedness - Additional Infor

Indebtedness - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement		$ 22,710,000
Senior secured credit facility term	5 years
Senior secured credit facility, maturity date	Jun. 17, 2018
Maximum
Debt Instrument [Line Items]
Capacity to increase borrowings under credit agreement	$ 65,373,000
Revolving Line of Credit
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement	200,000,000
Term Loan | Maximum
Debt Instrument [Line Items]
Accordion feature	$ 100,000,000

Unamortized Stock-Based Compens

Unamortized Stock-Based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 456	$ 1,427
Unamortized Stock-Based Compensation	2,912	6,762
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	89	115
Unamortized Stock-Based Compensation	$ 746	$ 1,336
Remaining Weighted Average Period (years)	1 year 8 months 12 days	2 years 8 months 12 days
Performance Based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 8	$ 42
Unamortized Stock-Based Compensation	$ 263	$ 499
Remaining Weighted Average Period (years)	1 year 8 months 12 days	2 years 9 months 18 days
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 326	$ 1,172
Unamortized Stock-Based Compensation	$ 1,462	$ 4,010
Remaining Weighted Average Period (years)	1 year 4 months 24 days	1 year 3 months 18 days
Performance Based Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 33	$ 98
Unamortized Stock-Based Compensation	$ 441	$ 917
Remaining Weighted Average Period (years)	1 year 3 months 18 days	1 year 10 months 24 days

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employees options granted	0
Stock-Based Compensation	$ 456	$ 1,427
Performance Based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	8	42
Nonvested unamortized stock-based compensation expense, value	$ 263	$ 499
Nonvested unamortized stock-based compensation expense, contractual term	1 year 8 months 12 days	2 years 9 months 18 days
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 89	$ 115
Nonvested unamortized stock-based compensation expense, value	$ 746	$ 1,336
Nonvested unamortized stock-based compensation expense, contractual term	1 year 8 months 12 days	2 years 8 months 12 days
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 33	$ 98
Nonvested unamortized stock-based compensation expense, contractual term	1 year 3 months 18 days	1 year 10 months 24 days
Number of shares issued to employees	52,170
Number of Shares, Granted		7,500
Weighted Average Grant-Date Fair Value, Granted		$ 10.96
Nonvested unamortized stock-based compensation other than options, value	$ 441	$ 917
Cliff vesting date		Jan. 5, 2018
Targeted performance percentage	200.00%	200.00%
Performance Shares | Performance Based Shares Related to Net Income Weighted at 50%, Net Sales Weighted at 30%, Commencing January 1, 2016 and Ending December 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted		$ 11.42
Performance Shares | Remaining 20% of Performance Based Shares are Based Upon AVD Stock Price Appreciation for the Period Commencing January 1, 2016 and Ending December 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted		$ 9.13
Performance Shares | Vested on January 6, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cliff vesting date	Jan. 6, 2019
Performance Shares | Performance Based Shares Based Upon Financial Performance of Earnings before Interest Tax ("EBIT") and Net Sales Goal for the Period Commencing January 1, 2016 and Ending December 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance	80.00%	80.00%
Earnings before income tax goal weight, percentage	50.00%	50.00%
Net sales goal weight, percentage	30.00%	30.00%
Performance Shares | Performance Based Shares Based Upon AVD Stock Price Appreciation Over the Course of the Period Commencing January 1, 2016, Ending December 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance	20.00%	20.00%
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation	$ 326	$ 1,172
Nonvested unamortized stock-based compensation expense, contractual term	1 year 4 months 24 days	1 year 3 months 18 days
Number of shares issued to employees	119,402
Number of years of service before cliff vesting	3 years	3 years
Number of Shares, Granted		30,000
Number of Shares, Vested	127,274	192,266
Weighted Average Grant-Date Fair Value, Granted		$ 11.42
Nonvested unamortized stock-based compensation other than options, value	$ 1,462	$ 4,010
Restricted Stock | Vest after 90 days
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Vested		7,500

Summary of Option Activity (Det

Summary of Option Activity (Detail)	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance | shares	626,845
Incentive Stock Option Plans, Option exercised | shares	(25,500)
Incentive Stock Option Plans, Option forfeited | shares	(9,813)
Incentive Stock Option Plans, Ending balance | shares	591,532
Weighted Average Price Per Share, Beginning balance	$ 9.25
Weighted Average Price Per Share, Option exercised	7.50
Weighted Average Price Per Share, Option forfeited	11.49
Weighted Average Price Per Share, Ending balance	9.29
Exercisable Weighted Average Price Per Share, Beginning balance	7.73
Exercisable Weighted Average Price Per Share, Ending balance	$ 7.84
Performance Based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance | shares	98,410
Incentive Stock Option Plans, Option forfeited | shares	(8,946)
Incentive Stock Option Plans, Ending balance | shares	89,464
Weighted Average Price Per Share, Beginning balance	$ 11.49
Weighted Average Price Per Share, Option forfeited	11.49
Weighted Average Price Per Share, Ending balance	$ 11.49

Summary of Stock Options Summar

Summary of Stock Options Summarized by Exercise Price (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Exercise Price	$ 9.29	$ 9.25
Exercisable Weighted Average, Exercise Price	$ 7.84	$ 7.73
Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares	591,532
Outstanding Weighted Average, Remaining Life (Months)	76 months
Outstanding Weighted Average, Exercise Price	$ 9.29
Exercisable Weighted Average, Shares	357,257
Exercisable Weighted Average, Exercise Price	$ 7.84
Incentive Stock Option Plan | Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	$ 7.50
Outstanding Weighted Average, Shares	331,750
Outstanding Weighted Average, Remaining Life (Months)	56 months
Outstanding Weighted Average, Exercise Price	$ 7.50
Exercisable Weighted Average, Shares	331,750
Exercisable Weighted Average, Exercise Price	$ 7.50
Incentive Stock Option Plan | Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	11.32
Exercise Price Per Share, Upper Range	$ 14.49
Outstanding Weighted Average, Shares	259,782
Outstanding Weighted Average, Remaining Life (Months)	101 months
Outstanding Weighted Average, Exercise Price	$ 11.57
Exercisable Weighted Average, Shares	25,507
Exercisable Weighted Average, Exercise Price	$ 12.28
Performance Based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares	89,464
Outstanding Weighted Average, Remaining Life (Months)	21 months
Outstanding Weighted Average, Exercise Price	$ 11.49
Performance Based Options | Range Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	$ 11.49
Outstanding Weighted Average, Shares	89,464
Outstanding Weighted Average, Remaining Life (Months)	21 months
Outstanding Weighted Average, Exercise Price	$ 11.49

Weighted Average Exercise Price

Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	591,532	626,845
Weighted Average Exercise Price, Outstanding	$ 9.29	$ 9.25
Weighted Average Exercisable, Exercise Price	$ 7.84	$ 7.73
Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	591,532
Number of Shares, Expected to Vest	582,606
Number of Shares, Exercisable	357,257
Weighted Average Exercise Price, Outstanding	$ 9.29
Weighted Average Exercise Price, Expected to Vest	9.25
Weighted Average Exercisable, Exercise Price	$ 7.84
Weighted Average Remaining Life, Outstanding	76 months
Weighted Average Remaining Contractual Life, Expected to Vest	76 months
Weighted Average Remaining Contractual Life, Exercisable	57 months
Intrinsic Value, Outstanding	$ 3,841
Intrinsic Value, Expected to Vest	3,803
Intrinsic Value, Exercisable	$ 2,836
Performance Based Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding	$ 11.49
Weighted Average Exercise Price, Expected to Vest	$ 11.49
Weighted Average Remaining Life, Outstanding	21 months
Weighted Average Remaining Contractual Life, Expected to Vest	21 months
Weighted Average Remaining Contractual Life, Exercisable	0 months
Intrinsic Value, Outstanding	$ 384
Intrinsic Value, Expected to Vest	$ 230

Summary of Non-Vested Shares (D

Summary of Non-Vested Shares (Detail) - Restricted Stock - $ / shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	362,841	560,842
Number of Shares, Granted		30,000
Number of Shares, Vested	(127,274)	(192,266)
Number of Shares, Forfeited	(16,008)	(422)
Number of Shares, Ending Balance	219,559	398,154
Weighted Average Grant-Date Fair Value, Beginning balance	$ 20.43	$ 21.44
Weighted Average Grant-Date Fair Value, Granted		11.42
Weighted Average Grant-Date Fair Value, Vested	31.29	20.47
Weighted Average Grant-Date Fair Value, Forfeited	23.67	14.92
Weighted Average Grant-Date Fair Value, Ending balance	$ 14.59	$ 21.17

Status Summary of Non-Vested Sh

Status Summary of Non-Vested Shares (Detail) - Performance Shares - $ / shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	104,403	103,907
Number of Shares, Granted		7,500
Number of Shares, Forfeited	(9,395)
Number of Shares, Ending Balance	95,008	111,407
Weighted Average Grant-Date Fair Value, Beginning balance	$ 17.05	$ 17.77
Weighted Average Grant-Date Fair Value, Granted		10.96
Weighted Average Grant-Date Fair Value, Forfeited	17.65
Weighted Average Grant-Date Fair Value, Ending balance	$ 16.99	$ 17.31

Litigation and Environmental -

Litigation and Environmental - Additional Information (Detail) $ in Millions	May. 12, 2015USD ($)
Schiemer Farms Matter
Loss Contingencies [Line Items]
Alleged loss of yield	$ 1.2

Beginning Balance, Annual Activ

Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	$ (3,541)	$ (1,970)
Other comprehensive gain (loss)	85	(248)
Ending Balance	$ (3,456)	$ (2,218)

Equity Method Investment - Addi

Equity Method Investment - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Equity Method Investments [Line Items]
Equity investment ownership position	15.11%
Gain loss from equity method investment	$ (82)
Carrying value of equity investment	2,454
Quoted market value of equity investment	$ 2,395

Equity Investment - Additional

Equity Investment - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2016USD ($)
Equity Method Investments [Line Items]
Equity investment ownership position	15.11%
Impairment on investment	$ 0
Bi-PA
Equity Method Investments [Line Items]
Equity investment ownership position	15.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Taxes [Line Items]
Income taxes (benefit) expense	$ 1,060	$ (292)
Effective tax rate	25.90%	87.20%